HK1005135A1 - Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative - Google Patents

Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative

Info

Publication number
HK1005135A1
HK1005135A1 HK98104339A HK98104339A HK1005135A1 HK 1005135 A1 HK1005135 A1 HK 1005135A1 HK 98104339 A HK98104339 A HK 98104339A HK 98104339 A HK98104339 A HK 98104339A HK 1005135 A1 HK1005135 A1 HK 1005135A1
Authority
HK
Hong Kong
Prior art keywords
derivative
water
ray diffraction
diffraction pattern
contg
Prior art date
Application number
HK98104339A
Other languages
English (en)
Inventor
Antoine Caron
Dominique Chantreux
Colette Bouloumie
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HK1005135A1 publication Critical patent/HK1005135A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
HK98104339A 1994-10-19 1998-05-19 Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative HK1005135A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412459A FR2725987B1 (fr) 1994-10-19 1994-10-19 Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Publications (1)

Publication Number Publication Date
HK1005135A1 true HK1005135A1 (en) 1998-12-24

Family

ID=9467986

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104339A HK1005135A1 (en) 1994-10-19 1998-05-19 Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative

Country Status (27)

Country Link
US (1) US5629331A (ko)
EP (1) EP0708103B1 (ko)
JP (1) JP3366786B2 (ko)
KR (1) KR100251222B1 (ko)
CN (1) CN1061656C (ko)
AT (1) ATE198478T1 (ko)
AU (1) AU698041B2 (ko)
CA (1) CA2160725C (ko)
CY (1) CY2277B1 (ko)
CZ (2) CZ288629B6 (ko)
DE (1) DE69519788T2 (ko)
DK (1) DK0708103T3 (ko)
ES (1) ES2155115T3 (ko)
FI (1) FI114156B (ko)
FR (1) FR2725987B1 (ko)
GR (1) GR3035503T3 (ko)
HK (1) HK1005135A1 (ko)
HU (1) HU226461B1 (ko)
IL (1) IL115688A (ko)
NO (1) NO307516B1 (ko)
NZ (1) NZ280293A (ko)
PL (1) PL184193B1 (ko)
PT (1) PT708103E (ko)
RU (1) RU2144536C1 (ko)
SI (1) SI0708103T1 (ko)
TW (1) TW357147B (ko)
ZA (1) ZA958850B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GEP20033114B (en) 1998-07-06 2003-11-25 Bristol Myers Squibb Co Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists, Method for Their Production and Pharmaceutical Compositions Containing the Same
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
CN1668612A (zh) * 2002-07-16 2005-09-14 特瓦制药工业有限公司 厄贝沙坦的新合成方法
CN101165062A (zh) * 2003-01-16 2008-04-23 特瓦制药工业有限公司 伊贝沙坦的新合成方法
DE602004015071D1 (de) 2003-02-05 2008-08-28 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4-on
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
WO2005051943A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Processes for the preparation of highly pure irbesartan
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006001026A1 (en) * 2004-06-23 2006-01-05 Hetero Drugs Limited Irbesartan polymorphs
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20090208573A1 (en) * 2004-11-11 2009-08-20 Lek Pharmaceuticals D.D Novel polymorph form of irbesartan
ES2259909B1 (es) * 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
EP1951714A1 (en) 2005-07-27 2008-08-06 Jubilant Organosys Limited Process for producing 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl- 4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
EP1806130B1 (en) 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
EP2065035B1 (en) * 2007-11-28 2010-07-21 Laboratorios Lesvi, S.L. Pharmaceutical formulations containing irbesartan
US20100234614A1 (en) * 2007-12-07 2010-09-16 Hetero Drugs Limited Process for pure irbesartan
KR101009383B1 (ko) * 2008-04-30 2011-01-19 켐젠주식회사 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법
EP2417110B1 (en) * 2009-04-08 2014-05-07 CTX Life Sciences Pvt. Ltd. A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4]non-1-en-4-one (irbesartan)
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
US8080670B2 (en) 2010-05-04 2011-12-20 Divi's Laboratories, Ltd. Process for the preparation of irbesartan
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
IL311793A (en) 2021-10-01 2024-05-01 Sanofi Sa A process for the preparation of active SARTAN compounds having a tetrazole ring

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2697919B2 (ja) * 1989-09-29 1998-01-19 キヤノン株式会社 信号内挿回路及び該回路を備えた変位測定装置
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds

Also Published As

Publication number Publication date
CZ288629B6 (cs) 2001-08-15
HUT73179A (en) 1996-06-28
FI954992A (fi) 1996-04-20
CZ271095A3 (en) 1996-05-15
ATE198478T1 (de) 2001-01-15
GR3035503T3 (en) 2001-06-29
NZ280293A (en) 1997-10-24
SI0708103T1 (en) 2001-04-30
ZA958850B (en) 1996-05-27
DK0708103T3 (da) 2001-04-23
RU2144536C1 (ru) 2000-01-20
KR960014122A (ko) 1996-05-22
JPH08208642A (ja) 1996-08-13
CA2160725A1 (en) 1996-04-20
CN1128261A (zh) 1996-08-07
NO954154L (no) 1996-04-22
AU3433595A (en) 1996-05-02
FI954992A0 (fi) 1995-10-19
FR2725987B1 (fr) 1997-01-10
EP0708103B1 (fr) 2001-01-03
CA2160725C (en) 2001-12-18
PT708103E (pt) 2001-06-29
FR2725987A1 (fr) 1996-04-26
IL115688A (en) 1999-09-22
NO307516B1 (no) 2000-04-17
CZ288624B6 (cs) 2001-08-15
JP3366786B2 (ja) 2003-01-14
PL184193B1 (pl) 2002-09-30
CY2277B1 (en) 2003-07-04
TW357147B (en) 1999-05-01
AU698041B2 (en) 1998-10-22
IL115688A0 (en) 1996-01-19
PL311012A1 (en) 1996-04-29
ES2155115T3 (es) 2001-05-01
CN1061656C (zh) 2001-02-07
NO954154D0 (no) 1995-10-18
FI114156B (fi) 2004-08-31
US5629331A (en) 1997-05-13
HU226461B1 (en) 2008-12-29
EP0708103A1 (fr) 1996-04-24
DE69519788D1 (de) 2001-02-08
KR100251222B1 (ko) 2000-05-01
DE69519788T2 (de) 2001-08-30
HU9503016D0 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
CY2277B1 (en) Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystallineform of this derivative
RU95118109A (ru) Способ получения производного тетразола, способ получения формы b производного тетразола, форма b производного тетразола и фармацевтическая композиция на основе производного тетразола формы b
ZA961677B (en) Method for recovery of xylose from solutions
CA2382406A1 (en) Substituted 2-arylbenzazole compounds and their use as antitumour agents
NO941857D0 (no) Tetrazolylfenylborsyremellomprodukter for syntese av AII-reseptorantagonister
ES2187483T3 (es) Procedimiento para la preparacion de acido a-lipoico esento de disolvente.
AU764260B2 (en) Method of producing cyclene
KR840003250A (ko) 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법
ZA847662B (en) 5h-(1)benzopyrano(2,3-d)pyrimidine derivatives,processes for their preparation,and their use in controlling lesions of gastric and duodenal mucous membranes
US6156890A (en) Process for the production of cyclene
HU0001558D0 (en) Process for the preparation of pirlindole hydrochloride
大江真道 et al. Changes in the characteristic of dry matter production of japonica type paddy rice (Oryza sativa L.) due to the deep-water treatment
CA2081135A1 (en) Method for precipitating an organic resin from an alkaline solution thereof
RU99113400A (ru) Способ очистки сточных вод
JPH1059960A (ja) 5−(アルコキシメチル)−2,3−ピリジンジカルボキシミド化合物の製造方法
Wang et al. Electrochemical method treatment of dye effluents containing NaCl of high concentration
WO1997001557A1 (fr) Procede de production de derives de biphenylmethane tetrazolyles
CA2114145A1 (en) New 3-/substituted tetrazolyl/-4-oxo-4h-pyrido-/1,2-a/- pyrimidines, salts thereof, pharmaceutical compositions containing them and process for preparing same

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141018